1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1161/CIRCRESAHA.111.300440" target="_blank" rel="noreferrer noopener">http://doi.org/10.1161/CIRCRESAHA.111.300440</a>
Pages
816–825
Issue
5
Volume
112
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.
Publisher
An entity responsible for making the resource available
Circulation research
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-03
Subject
The topic of the resource
*Plasmids; Aged; Brain/blood; Chemokine CXCL12/*genetics/metabolism; Cohort Studies; Dose-Response Relationship; Drug; Echocardiography; Exercise Tolerance; Female; Follow-Up Studies; Genetic Therapy/*adverse effects/*methods; Heart Failure/metabolism/pathology/*therapy; Humans; Male; Middle Aged; Myocardium/metabolism/pathology; Natriuretic Peptide; Peptide Fragments/blood; Positron-Emission Tomography; Quality of Life; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Penn Marc S; Mendelsohn Farrell O; Schaer Gary L; Sherman Warren; Farr Maryjane; Pastore Joseph; Rouy Didier; Clemens Ruth; Aras Rahul; Losordo Douglas W
Description
An account of the resource
RATIONALE: Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1. OBJECTIVE: We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters. METHODS AND RESULTS: Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1161/CIRCRESAHA.111.300440" target="_blank" rel="noreferrer noopener">10.1161/CIRCRESAHA.111.300440</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Plasmids
2013
Aged
Aras Rahul
Brain/blood
Chemokine CXCL12/*genetics/metabolism
Circulation research
Clemens Ruth
Cohort Studies
Dose-Response Relationship
Drug
Echocardiography
Exercise Tolerance
Farr Maryjane
Female
Follow-Up Studies
Genetic Therapy/*adverse effects/*methods
Heart Failure/metabolism/pathology/*therapy
Humans
Losordo Douglas W
Male
Mendelsohn Farrell O
Middle Aged
Myocardium/metabolism/pathology
Natriuretic Peptide
Pastore Joseph
Penn Marc S
Peptide Fragments/blood
Positron-Emission Tomography
Quality of Life
Rouy Didier
Schaer Gary L
Sherman Warren
Treatment Outcome